<DOC>
	<DOCNO>NCT01625455</DOCNO>
	<brief_summary>The purpose randomize , double-blinded , placebo-controlled study test hypothesis administration aprepitant decrease severity pruritus patient SÃ¨zary Syndrome .</brief_summary>
	<brief_title>Effect Neurokinin-1 Receptor ( NK1R ) Antagonism Pruritus Patients With Sezary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Known Sezary Syndrome Pruritus uncontrolled conventional treatment . Baseline visual analogue scale &gt; 4 . Age 18 80 year age . Stable medication regimen Sezary Syndrome pruritus 3 month prior study participation . Known hepatic impairment ( define liver function test &gt; 3 time upper limit normal ) . Pregnancy ( woman childbearing potential undergo urine betahcg test ) . Concurrent use pimozide , terfenadine , astemizole , cisapride .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Sezary Syndrome</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Neurokinin-1</keyword>
</DOC>